ReVision Optics (RVO), a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.
The Vue+ study will evaluate 400 presbyopic subjects for three years. The investigators for Phase I included Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas, and Dr. Jon Dishler of the Dishler Laser Institute in Greenwood Village, Colorado. RVO anticipates that Dr. Dan Tran, of the Coastal Laser Eye Center in Newport Beach, California; Dr. Y Ralph Chu of the Chu Vision Institute in Minneapolis, Minnesota; Dr. John F. Doane, of the Discover Vision Center in Leawood, Kansas; Dr. John Olkowski, of the EyeSight Vision Institute, in Honolulu, Hawaii; and Dr. Robert Lehmann of the Lehmann Eye Center in Nacogdoches, Texas, will participate as investigators after FDA approval to expand the trial.
Presbyopia is a common vision problem that affects everyone as they age. When people become older their eyes naturally lose the ability to focus, which typically happens around age 45. For people with good distance vision, symptoms of presbyopia can include difficulty seeing things close up like newspapers, menus and computer screens. Currently, more than 73 million people in the US are presbyopic.